TIDMSKIN
RNS Number : 1526S
Integumen PLC
29 September 2017
29 September 2017
Integumen plc
("Integumen", the "Group" or "Company")
INTERIM RESULTS
Integumen (LSE: SKIN), the personal health care company
developing and commercialising technology and products for the
human integumentary system today announces its interim results for
the 6 months ended 30 June 2017.
Performance Highlights
-- Completed the integration of the four acquired businesses and
have continued to successfully commercialise the first series of
products within skincare and oral care;
-- Launched TSPro's brand in South Korea through a strategic
supply agreement with Mono Dent, a leading distributor of oral
hygiene products in South Korea;
-- Received orders from reputable blue chip clients with an
ever-increasing focus on the human microbiome and R&D in
skincare:
o Conducted efficacy trials for La Prairie, a leading
Swiss-based beauty company, which has been using Labskin,
Integumen's human skin equivalent model, as a platform to test
certain materials in their product range;
o Signed a Labskin evaluation order with Merck, an international
developer, manufacturer and distributor of pharmaceuticals;
o Recevied an order from Galderma, a pharmaceutical subsidiary
specializing in the research, development and marketing of
dermatological treatments, which is a wholly-owned subsidiary of
Nestlé testing of materials and formulations in their HQ in
Lausanne, Switzerland.
Financial Results for the 6 months ended 30 June 2017
-- Revenues of GBP124,310 and EBITDA loss of GBP740,167 after
administrative costs of GBP1,476,057, which included one-off costs
of GBP274,893 associated with the Company's listing on AIM,
amortization and depreciation of assets of GBP371,727 and continued
investment in Visible Youth, Labskin and TSPro;
-- Operating loss of GBP1,386,787;
-- As at 30 June 2017 the Group had total assets of GBP9,872,563;
-- During the period the Group raised GBP2.25m through our April
flotation on AIM of the London Stock Exchange, which we are using
for product development, sales & marketing and working
capital;
Post Period end
-- Received a Notice of Allowance ("NOA") for the trademark
"Clarogel" in the United States of America. Clarogel is an
antimicrobial formulation of usnic acid which is a late stage
product designed for blemish control;
-- Received NOA for Visible Youth patent in Canada, for the
cosmetic composition for the treatment of skin. Visible Youth is a
range of cosmeceuticals targeting the anti-ageing market;
-- Received a patent in the United States for the manufacture
and sale of TS1, a tongue vacuum cleaner;
-- Signed a worldwide Patent Licence Agreement with Dr Gary Hack
for his co-rights to various patents and know-how related to
botulinum toxin (commonly known as Botox) treatments, dermal
fillers and the "Botox Booster IP".
Integumen plc Declan Service, CEO + 353 (0) 87 770 5506
SPARK Advisory Partners
Limited
(Nominated Adviser) Neil Baldwin/Sean Wyndham-Quin +44 (0) 113 370 8974
-------------------------------- ----------------------------------
Turner Pope Investments
(TPI) Ltd Ben Turner/James Pope +44 (0) 20 3621 4120
-------------------------------- ----------------------------------
Cardew Group Shan Shan Willenbrock +44 (0) 20 7930 0777
David Roach mailto:integumen@cardewgroup.com
-------------------------------- ----------------------------------
Integumen Plc
Chairman's Statement
Introduction
I am pleased to report our half year results for the 6 months
ended 30 June 2017, during which Integumen has undergone
significant changes. The Group successfully integrated the four
businesses acquired to assemble an attractive portfolio of
products, technologies and associated know-how within skincare,
oral care and wound care. Following our admission to trading on the
AIM market of London Stock Exchange plc on 5 April 2017 from which
we raised funds of GBP2.25 million, we continue to successfully
commercialise the TS1 tongue sanitiser and Labskin, our human skin
equivalent technology which targets the cosmetic product testing
sector.
To date, approximately GBP15 million has been invested by
various previous owners in developing the Group's products and
technologies which are at the late stages of development, meaning
the majority of risk associated with commercialisation was
mitigated before we came to market. Additionally, our portfolio of
products does not require traditional phases 1-4 clinical trials
reducing further commercial and clinical risks.
Operational Performance
In oral care, we launched the TS1 brand in South Korea, a
country with approximately 20,000 dental surgeries and a growing
market driven by medical tourism and cosmetic dental surgery.
During the period, we signed a strategic supply agreement with Mono
Dent, a leading distributor of oral hygiene products to dental
surgeries and dental universities in the country, for an initial
term of three years. The agreement provides Mono Dent with the
exclusive rights to distribute three products under the TS1 brand
within South Korea; a disposable tongue vacuum cleaner for
professional use in the dental surgery, a tongue gel and a handle
which turns the tongue vacuum cleaner into a tongue cleanser for
home-use. As part of the exclusive agreement, Mono Dent committed
to a sales and marketing strategy for TS1 to penetrate further the
South Korean market, with an initial delivery of 49,000 units
Demand from blue chip clients with an increasing focus on the
human microbiome and R&D in skincare, has driven sales in
Labskin during the period. Integumen signed three orders during the
period. La Prairie, a leading Swiss-based beauty company, placed
orders for Integumen to conduct efficacy trials, using Labskin as
the platform to test certain materials in their product range.
Since the EU ban on testing of cosmetics on animals, the Company
has become ideally positioned to take advantage of the fact that
human skin equivalents like Labskin are being increasingly used by
developers operating in the dermatology space such as La
Prairie.
Similarly, Merck, the international developer, manufacturer and
distributor of pharmaceuticals, signed an evaluation order with
Integumen for its Labskin human skin equivalent model, and
Galderma, the pharmaceutical subsidiary specializing in the
research, development and marketing of dermatological treatments,
which is a wholly-owned subsidiary of Nestlé, ordered Labskin for
testing materials and formulations in their HQ in Lausanne,
Switzerland.
The Company continues to develop products that will target
consumers in the skincare market. These products are in the late
stages of development with Visible Youth, a premium cosmeceutical
for the anti-ageing market, planned for launch in 2018; Clarogel,
an over-the-counter cosmetic product for the treatment of
blemishes, planned for commercialisation in 2019; and Wound pHase,
a chronic wound diagnostic tool, and Hydrogel, a material used for
the treatment of wounds, both scheduled for launch in 2020.
Since the period end, the Company was pleased to announce that
it received a NOA for its base Visible Youth patent in Canada, for
the cosmetic composition for the treatment of skin. These
compositions include the combination of Hyaluronic acid and
bioactive glass powder which form the basis of Integumen's line of
Visible Youth products, a range of cosmeceuticals targeting the
anti-ageing market. We also announced that we have received a NOA
for the trademark of "Clarogel" in the United States of America, an
anti-microbial formulation of usnic acid which is a late stage
product designed for blemish control.
Since the period end, we also received a patent in the United
States for the manufacture and sale of TS1, a tongue vacuum
cleaner, and signed a worldwide Patent Licence Agreement with Dr
Gary Hack for his co-rights to various patents and know-how related
to enhancing and extending the cosmetic benefits of botulinum toxin
(commonly known as Botox) treatments as well as dermal fillers and
rosacea known as the "Botox Booster IP".
Outlook
The Board and senior management team are enthusiastic about the
medium to long-term prospects of Integumen, which is a young
company operating in markets that provide us with significant
opportunities to sell our portfolio of quality products, and we
look forward to updating shareholders as we progress on this
exciting journey.
Tony Richardson
Chairman 29 September 2017
Integumen Plc
Consolidated Statement of Comprehensive Income
For the 6 months ended 30 June 2017
Unaudited
6 months Unaudited Audited
ended 6 months ended Year ended
30 June 30 June 31 December
2017 2016 2016
GBP GBP GBP
----------------------------------- ------------ ---------------- -------------
Revenue 124,310 27,315 52,062
Costs of sales (35,040) (44,337) (62,716)
----------------------------------- ------------ ---------------- -------------
Gross (loss)/profit 89,270 (17,022) (10,654)
Administrative Costs (1,476,057) (518,857) (1,207,488)
Deemed reverse acquisition costs - - 141,064
Operating loss (1,386,787) (535,879) (1,077,078)
----------------------------------- ------------ ---------------- -------------
Depreciation 31,972 17,005 33,747
Amortisation 339,755 26,742 85,214
Exceptional items 274,893 - 184,916
EBITDA before exceptional items (740,167) (492,132) (773,201)
----------------------------------- ------------ ---------------- -------------
Finance costs (18,689) (2,698) (17,523)
Loss before income tax (1,405,476) (538,577) (1,094,601)
Income tax credit 26,946 47,129 48,440
----------------------------------- ------------ ---------------- -------------
Loss for the period (1,378,530) (491,448) (1,046,161)
----------------------------------- ------------ ---------------- -------------
Other comprehensive income
----------------------------------- ------------ ---------------- -------------
Currency translation differences (164,475) (22,543) (20,657)
----------------------------------- ------------ ---------------- -------------
Total comprehensive loss for the
period (1,543,005) (513,991) (1,066,818)
----------------------------------- ------------ ---------------- -------------
Loss per share attributable to owners
of the parent during the period
Basic and diluted loss per ordinary share 1.1p 1.4p 2.6p
------------------------------------------- ----- ----- -----
Integumen Plc
Consolidated Statement of Financial Position
As at 30 June 2017
Unaudited Unaudited Audited
As at As at As at
30 June 30 June 31 December
2017 2016 2016
GBP GBP GBP
-------------------------------- --- ------------ ------------ -------------
Assets
Non-current assets
Intangible assets 8,711,850 583,424 4,558,194
Property, plant and equipment 281,023 104,459 87,601
Investments in subsidiaries - - -
Loan to subsidiary undertaking - - -
Total non-current assets 8,992,873 687,883 4,645,795
------------------------------------- ------------ ------------ -------------
Current assets
Inventories 12,803 8,854 11,203
Trade and other receivables 354,946 270,967 309,129
Cash and cash equivalents 511,941 46,201 30,039
------------------------------------- ------------ ------------ -------------
Total current assets 879,690 326,022 350,371
------------------------------------- ------------ ------------ -------------
Total assets 9,872,563 1,013,905 4,996,166
------------------------------------- ------------ ------------ -------------
Equity attributable to owners
Share capital 1,658,602 194 7,365,324
Share premium account 1,750,537 745,645 -
Retained loss (3,291,170) (1,357,926) (1,912,639)
Foreign currency reserve (185,132) (22,543) (20,657)
Reverse acquisition reserve (2,843,135) - (2,843,135)
Capital redemption reserve 9,519,063 - -
Share based equity reserve 7,857 - -
------------------------------------- ------------ ------------ -------------
Total equity 6,616,622 (634,630) 2,588,893
------------------------------------- ------------ ------------ -------------
Liabilities
Non-current liabilities
Deferred tax liabilities 847,413 - 93,069
Borrowings 636,113 32,240 667,024
Total non-current liabilities 1,483,526 32,240 760,093
------------------------------------- ------------ ------------ -------------
Current liabilities
Trade and other payables 1,368,969 1,586,534 1,445,407
Deferred tax liabilities 97,296 - 10,486
Borrowings 306,149 29,761 191,287
Total current liabilities 1,772,414 1,616,295 1,647,180
------------------------------------- ------------ ------------ -------------
Total liabilities 3,255,941 1,648,535 2,407,273
------------------------------------- ------------ ------------ -------------
Total equity and liabilities 9,872,563 1,013,905 4,996,166
------------------------------------- ------------ ------------ -------------
Integumen Plc
Consolidated Statement of Cash Flows
For the 6 months ended 30 June 2017
Unaudited Unaudited Audited
6 months 6 months Year
ended ended ended
30 June 30 June 31 December
2017 2016 2016
GBP GBP GBP
Cash Flow from operating activities
---------------------------------------------- ------ ------------ ---------- -------------
Cash (used in)/generated from operations (1,503,070) 52,009 (975,267)
Taxation - 47,129 6,930
Interest paid (18,689) (2,698) (17,523)
Net cash (used in)/generated from
operating activities (1,521,759) 96,440 (985,860)
------------------------------------------------------ ------------ ---------- -------------
Cash flow from investing activities
Payments to acquire intangibles (51,788) (70,391) (945,032)
Purchase of property, plant and equipment - (1,604) (1,604)
Payments to acquire subsidiary undertakings (63,150) - -
Net cash used in investing activities (114,938) (71,995) (946,636)
------------------------------------------------------ ------------ ---------- -------------
Cash flow from financing activities
Proceeds from issuance of ordinary
shares 2,208,553 - 1,144,468
New loans - - 858,402
Repayment of loans (76,133) - -
Capital element of finance lease (12,271) - (24,542)
Repayments on borrowings (1,551) (1,400) (38,949)
Net cash generated by financing activities 2,118,598 (1,400) 1,939,379
------------------------------------------------------ ------------ ---------- -------------
Net increase/ (decrease) in cash
and cash equivalents 481,901 23,045 6,883
Cash and cash equivalents at beginning
of period 30,039 23,156 23,156
Cash and cash equivalents at end
of period 511,941 46,201 30,039
------------------------------------------------------ ------------ ---------- -------------
Integumen Plc
Consolidated Statement of Changes in Shareholders' Equity
Capital Share
Group Foreign Reverse redemption based
Share Share Retained currency acquisition reserve equity
capital premium earnings reserve reserve reserve Total
GBP GBP GBP GBP GBP GBP GBP GBP
--------------- ------------ -------------------- ------------ ---------- ------------ ----------- -------- ------------
At 1 January
2016 194 745,645 (866,478) - - - - (120,639)
--------------- ------------ -------------------- ------------ ---------- ------------ ----------- -------- ------------
Changes in
equity
for the 6
months
ended 30 June
2016
Loss for the
period - - (491,448) - - - - (491,448)
Currency
translation
differences - - - (22,543) - - - (22,543)
--------------- ------------ -------------------- ------------ ---------- ------------ ----------- -------- ------------
Total
comprehensive
loss
for the year - - (491,448) (22,543) - - - (513,991)
--------------- ------------ -------------------- ------------ ---------- ------------ ----------- -------- ------------
At 30 June
2016 194 745,645 (1,357,926) (22,543) - - - (634,630)
--------------- ------------ -------------------- ------------ ---------- ------------ ----------- -------- ------------
Changes in
equity
for the 6
months
ended 31
December
2016
Loss for the
period - - (554,713) - - - - (554,713)
Currency
translation
differences - - - 1,886 - - - 1,886
--------------- ------------ -------------------- ------------ ---------- ------------ ----------- -------- ------------
Total
comprehensive
loss
for the year - - (554,713) 1,886 - - - (552,827)
--------------- ------------ -------------------- ------------ ---------- ------------ ----------- -------- ------------
Transactions
with
the owners
Shares issued
during
the year 7,365,400 1,144,392 - - - - - 8,509,792
Reverse
acquisition
arising (270) (1,890,037) - - (2,843,135) - - (4,733,442)
--------------- ------------ -------------------- ------------ ---------- ------------ ----------- -------- ------------
Total
contributions
by and
distributions
to
owners 7,365,130 (745,645) - - (2,843,135) - - 3,776,350
--------------- ------------ -------------------- ------------ ---------- ------------ ----------- -------- ------------
At 31 December
2016 7,365,324 - (1,912,639) (20,657) (2,843,135) - - 2,588,893
--------------- ------------ -------------------- ------------ ---------- ------------ ----------- -------- ------------
Changes in
equity
for the 6
months
ended 30 June
2017
Loss for the
period - - (1,378,530) - - - - (1,378,530)
Currency
translation
differences - - - (164,475) - - - (164,475)
--------------- ------------ -------------------- ------------ ---------- ------------ ----------- -------- ------------
Total
comprehensive
loss
for the year - - (1,378,530) (164,475) - - - (1,543,005)
--------------- ------------ -------------------- ------------ ---------- ------------ ----------- -------- ------------
Transactions
with
the owners
Shares issued
during
the period 3,812,341 1,832,000 - - - - - 5,644,341
Commission on
Share
Issue (81,463) - - - - - (81,463)
Cancelled
Shares (9,519,063) - - - - 9,519,063 - -
Share option
based
charge - - - - - - 7,857 7,857
--------------- ------------ -------------------- ------------ ---------- ------------ ----------- -------- ------------
Total
contributions
by and
distributions
to
owners 3,812,341 1,750,537 - - - 7,857 5,570,735
--------------- ------------ -------------------- ------------ ---------- ------------ ----------- -------- ------------
At 30 June
2017 1,658,602 1,750,537 (3,291,170) (185,132) (2,843,135) 9,519,063 7,857 6,616,622
--------------- ------------ -------------------- ------------ ---------- ------------ ----------- -------- ------------
Integumen Plc
Notes to the Financial Statements
For the 6 months ended 30 June 2017
1. General information
Integumen Plc is a company incorporated in England and Wales.
The Company is a public limited company admitted to trading on the
AIM market of the London Stock Exchange since 5 April 2017. The
address of the registered office is Sand Hutton Applied Innovation
Campus, Sand Hutton, York, North Yorkshire, YO41 1LZ.
The principal activity of the Group is that of developing
technologies in the skin industry. The Group has a presence in the
UK, Ireland and Germany.
The financial statements are presented in pounds sterling, the
currency of the primary economic environment in which the Group's
trading companies operate.
The registered number of the Company is 10205396.
2. Basis of preperation
The financial information in these interim results is that of
the holding company and all of its subsidiaries. It has been
prepared in accordance with the recognition and measurement
requirements of International Financial Reporting Standards as
adopted for use in the EU (IFRSs). The accounting policies applied
by the Group in this financial information are the same as those
applied by the Group in its financial statements for the year ended
31 December 2016 and which will form the basis of the 2017
financial statements except for a number of new and amended
standards which have become effective since the beginning of the
previous financial year. These new and amended standards are not
expected to materially affect the Group.
The financial information presented herein does not constitute
full statutory accounts under Section 434 of the Companies Act 2006
and was not subject to a formal review by the auditors. The
financial information in respect of the year ended 31 December 2016
has been extracted from the statutory accounts which have been
delivered to the Registrar of Companies. The Group's Independent
Auditor's report on those accounts was unqualified, did not include
references to any matters to which the auditor drew attention by
way of emphasis without qualifying their report and did not contain
a statement under section 498(2) or 498(3) of the Companies Act
2006. The financial information for the half years ended 30 June
2017 and 30 June 2016 is unaudited and the twelve months to 31
December 2016 is audited.
3. Basis of consolidation
The consolidated financial statements incorporate the financial
statements of the Company and its subsidiary and associated
undertakings. Subsidiaries are all entities over which the Group
has the power to govern their financial and operating policies
generally accompanying a shareholding of more than fifty per cent
of the voting rights. The existence and effect of potential voting
rights that are currently exercisable or convertible are considered
when assessing whether the Group controls another entity.
Subsidiaries are fully consolidated from the date on which control
is transferred to the Group. They are de-consolidated from the date
that control ceases.
Inter-company transactions, balances and unrealised gains on
transactions between Group companies are eliminated. Unrealised
losses are also eliminated. Accounting policies of subsidiaries
have been changed where necessary to ensure consistency with the
policies adopted by the Group.
The Group's share of post-acquisition profit or loss is
recognised in the income statement, and its share of
post-acquisition movements in other comprehensive income is
recognised in the comprehensive income with a corresponding
adjustment in the carrying amount of the investment.
(a) Acquisition accounting
The Group uses the acquisition method of accounting to account
for business combinations. The consideration transferred for the
acquisition of a subsidiary is the fair values of the assets
transferred, the liabilities incurred and the equity interests
issued by the Group. The consideration transferred includes the
fair value of any asset or liability resulting from a contingent
consideration agreement. Acquisition related costs are expensed as
incurred. Identifiable assets acquired and liabilities and
contingent liabilities assumed in a business combination are
measured initially at their fair values at the acquisition
date.
Integumen Plc
Notes to the Financial Statements (continued)
For the 6 months ended 30 June 2017
On an acquisition by acquisition basis, the Group recognises any
non-controlling interest in the acquiree either at fair value or at
the non-controlling interest's proportionate share of the
acquiree's net assets.
The excess of the consideration transferred, the amount of any
non-controlling interest in the acquiree and the acquisition date
fair value of any previous equity interest in the acquiree over the
fair value of the Group's share of the identifiable net assets
acquired is recorded as goodwill. If this is less than the fair
value of the net assets of the subsidiary acquired in the case of a
bargain purchase, the difference is recognised directly in the
income statement.
Investments in subsidiaries are accounted for at cost less
impairment. Cost is adjusted to reflect changes in consideration
arising from contingent consideration amendments.
(b) Reverse acquisition accounting
The acquisition of Innovenn UK Limited and its subsidiary by
Integumen Plc on 17 November 2016 has been accounted using the
principles of reverse acquisition accounting. Although the Group
financial statements have been prepared in the name of the legal
parent, Integumen Plc, they are in substance a continuation of the
consolidated financial statements of the legal subsidiary, Innovenn
UK Limited. The following accounting treatment has been applied in
respect of the reverse accounting:
The assets and liabilities of the legal subsidiary, Innovenn UK
Limited are recognised and measured in the Group financial
statements at the pre-combination carrying amounts, without
restatement of fair value. The retained earnings and other equity
balances recognised in the Group financial statements reflect the
retained earnings and other equity balances of Innovenn UK Limited
immediately before the business combination and the results of the
period from 1 January 2014 to the date of the business combination
are those of Innovenn UK Limited. However, the equity structure
appearing in the Group financial statements reflects the equity
structure of the legal parent, Integumen Plc, including the equity
instruments issued in order to effect the business combination.
The Group's comparative figures for the 6 months ended 30 June
2016 presented in these financial statements are therefore the
consolidated numbers of Innovenn UK Limited.
4. Exceptional items
Included within administrative expenses are exceptional items as
shown below:
Unaudited Unaudited
6 months 6 months Audited
ended ended Year ended
30 June 30 June 31 December
2017 2016 2016
--------------------------------------------- ---------- ---------- -------------
Exceptional items include:
- Transaction costs relating to listing and
business acquisition 274,893 - 325,980
- Deemed credit on reverse acquisition - - (141,064)
--------------------------------------------- ---------- ---------- -------------
Total exceptional items 274,893 - 184,916
--------------------------------------------- ---------- ---------- -------------
Integumen Plc
Notes to the Financial Statements (continued)
For the 6 months ended 30 June 2017
5. Loss per share
(a) Basic
Basic loss per share is calculated by dividing the loss
attributable to equity holders of the Company by the weighted
average number of ordinary shares in issue during the year.
Unaudited Unaudited
6 months 6 months Audited
ended ended Year ended
30 June 30 June 31 December
2017 2016 2016
Loss attributable to owners of the parent GBP1,378,530 GBP491,448 GBP1,046,161
Weighted average number of Ordinary Shares
in issue 124,221,627 34,839,803 40,584,133
-------------------------------------------- ------------- ----------- -------------
Basic loss per share 1.1p 1.4p 2.6p
-------------------------------------------- ------------- ----------- -------------
(b) Diluted
There were no dilutive potential ordinary shares in issue at the
period end.
6. Dividends
There were no dividends paid or proposed by the Company.
7. Intangible fixed assets
Group Development Costs
and Intellectual
Property Rights Total
GBP GBP
---------------------------------------------- ------------------ -----------
Cost
At 1 January 2017 4,689,566 4,689,566
On acquisition of subsidiary 4,600,649 4,600,649
Additions(1) 51,788 51,788
Exchange differences (164,081) (164,081)
At 30 June 2017 9,177,922 9,177,922
---------------------------------------------- ------------------ -----------
Amortisation
At 1 January 2017 131,372 131,372
Charge for the year 339,755 339,755
Exchange differences (5,054) (5,054)
At 30 June 2017 466,073 466,073
---------------------------------------------- ------------------ -----------
Net book value
At 31 December 2016 4,588,194 4,588,194
---------------------------------------------- ------------------ -----------
At 30 June 2017 8,711,850 8,711,850
---------------------------------------------- ------------------ -----------
(1) Additions are development costs capitalised during the
period
Integumen Plc
Notes to the Financial Statements (continued)
For the 6 months ended 30 June 2017
8. Deferred income tax
Deferred tax liabilities
Deferred tax balances were as follows:
Unaudited Unaudited
6 months 6 months Audited
ended ended Year ended
30 June 30 June 31 December
2017 2016 2016
----------------------------------------------- ---------- ---------- -------------
Deferred tax liability to be recovered after
more than one year 847,413 - 93,069
Deferred tax liability to be recovered within
one year 97,296 - 10,486
----------------------------------------------- ---------- ---------- -------------
944,709 - 103,555
----------------------------------------------- ---------- ---------- -------------
Deferred tax liabilities were made up as
follows:
Accelerated tax depreciation 944,709 - 103,555
----------------------------------------------- ---------- ---------- -------------
944,709 - 103,555
----------------------------------------------- ---------- ---------- -------------
The movement on the deferred income tax account is as
follows:
Unaudited Unaudited
6 months 6 months Audited
ended ended Year ended
30 June 30 June 31 December
2017 2016 2016
-------------------------------- ---------- ---------- -------------
Balance at beginning of period 103,555 - -
On acquisition of subsidiary 868,100 - 104,866
Income statement movement (26,946) - (1,311)
-------------------------------- ---------- ---------- -------------
944,709 - 103,555
-------------------------------- ---------- ---------- -------------
9. Share capital
Unaudited Unaudited
6 months 6 months Audited
ended ended Year ended
30 June 30 June 31 December
2017 2016 2016
GBP GBP GBP
---------------------------------------- ---------- ---------- -------------
7,365,324 Ordinary shares of GBP1 each - - 7,365,324
194 ordinary shares GBP1 each - 194 -
165,860,248 Ordinary shares of 1p each 1,658,602 - -
Total 1,658,602 194 7,365,324
---------------------------------------- ---------- ---------- -------------
Integumen Plc
Notes to the Financial Statements (continued)
For the 6 months ended 30 June 2017
The Group's comparative figures for share capital for the 6
months ended 30 June 2016 presented in these financial statements
are the consolidated numbers of Innovenn UK Limited.
During the period ended 30 June 2017, the following changes to
the company's share capital took place:
- On 24 March 2017, the Company issued 3,354,325 ordinary shares
of GBP1 to acquire the shares in TSPro GmbH.
- On 24 March 2017, the Company issued 16 ordinary shares of
GBP1 to certain shareholders of the company.
- On 24 March 2017, each ordinary existing share of GBP1 was
sub-divided into one deferred share of 84.32p and one ordinary
share of 15.68p. Each ordinary share of 15.68p was then subdivided
into 56 ordinary shares of 1.4p each for every 5 in issue, and all
of the deferred shares were cancelled and extinguished. Each
ordinary share of 1.4p was then sub-divided into 1 ordinary share
of 1p each and 1 deferred share of 0.4p, and all of the deferred
shares were cancelled and extinguished.
- On 5 April 2017, the Company's ordinary shares of 1p each were
admitted to trading on the AIM market of London Stock Exchange plc
with ISIN number GB00BYWJ6269. On Admission the Company issued
45,000,000 ordinary shares of 1p each at a placing price of 5p per
ordinary share raising a total of GBP2.25 million.
- On 11 April 2017, the Company issued 800,000 ordinary shares of 1p each.
As at 30 June 2017, the Company had an issued share capital of
165,860,248 ordinary shares of 1p each.
10. Post balance sheet events
There have been no significant events affecting the company
since the period-end
11. Availability of announcement
A copy of this announcement is available from the Company's
website, being www.integumenplc.com.
This information is provided by RNS
The company news service from the London Stock Exchange
END
IR EASNPALAXEFF
(END) Dow Jones Newswires
September 29, 2017 02:00 ET (06:00 GMT)
Integumen (LSE:SKIN)
Historical Stock Chart
From Apr 2024 to May 2024
Integumen (LSE:SKIN)
Historical Stock Chart
From May 2023 to May 2024